Medizinische Universität Graz - Research portal

Logo MUG Resarch Portal

Selected Publication:

SHR Neuro Cancer Cardio Lipid Metab Microb

Gkika, E; Schultheiss, M; Bettinger, D; Maruschke, L; Neeff, HP; Schulenburg, M; Adebahr, S; Kirste, S; Nestle, U; Thimme, R; Grosu, AL; Brunner, TB.
Excellent local control and tolerance profile after stereotactic body radiotherapy of advanced hepatocellular carcinoma.
Radiat Oncol. 2017; 12(1):116 Doi: 10.1186/s13014-017-0851-7 [OPEN ACCESS]
Web of Science PubMed PUBMED Central FullText FullText_MUG

 

Co-authors Med Uni Graz
Brunner Thomas Baptist
Altmetrics:

Dimensions Citations:

Plum Analytics:

Scite (citation analytics):

Abstract:
BACKGROUND: To evaluate the efficacy and toxicity of stereotactic body radiotherapy (SBRT) in the treatment of advanced hepatocellular carcinoma (HCC). MATERIAL AND METHODS: Patients with large HCCs (median diameter 7 cm, IQR 5-10 cm) with a Child-Turcotte-Pugh (CTP) score A (60%) or B (40%) and Barcelona-Clinic Liver Cancer (BCLC) classification stage B or C were treated with 3 to 12 fractions to allow personalized treatment according to the size of the lesions and the proximity of the lesions to the organs at risk aiming to give high biologically equivalent doses assuming an α/β ratio of 10 Gy for HCC. Primary end points were in-field local control and toxicity assessment. RESULTS: Forty seven patients with 64 lesions were treated with SBRT (median 45 Gy in 3-12 fractions) with a median follow up for patients alive of 19 months. The median biological effective dose was 76 Gy (IQR 62-86 Gy). Tumor vascular thrombosis was present in 28% and an underlying liver disease in 87% (hepatitis B or C in 21%, alcohol related in 51%, nonalcoholic steatohepatitis in 13% of the patients, primary biliary cirrhosis 2%). Eighty three percent received prior and in most cases multiple therapies. Local control at 1 year was 77%. The median overall survival from the start of SBRT was 9 months (95% CI 7.7-10.3). Gastrointestinal toxicities grade ≥ 2 were observed in 3 (6.4%) patients. An increase in CTP score without disease progression was observed in 5 patients, of whom one patient developed a radiation induced liver disease. One patient died due to liver failure 4 months after treatment. CONCLUSION: SBRT is an effective local ablative therapy which leads to high local control rates with moderate toxicity for selected patients with large tumors.
Find related publications in this database (using NLM MeSH Indexing)
Adult - administration & dosage
Aged - administration & dosage
Aged, 80 and over - administration & dosage
Carcinoma, Hepatocellular - surgery
Dose Fractionation, Radiation - administration & dosage
Female - administration & dosage
Follow-Up Studies - administration & dosage
Humans - administration & dosage
Liver Neoplasms - surgery
Male - administration & dosage
Middle Aged - administration & dosage
Organs at Risk - radiation effects
Prognosis - administration & dosage
Radiosurgery - administration & dosage
Retrospective Studies - administration & dosage
Survival Rate - administration & dosage

Find related publications in this database (Keywords)
Stereotactic body radiotherapy
SBRT
Hepatocellular carcinoma
HCC
SIP
© Med Uni GrazImprint